Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication

Addiction

Volumn 107, Issue SUPPL.1, 2012, Pages 45-52

  Kaltenbach, Karol ^a   Holbrook, Amber M ^a   Coyle, Mara G ^b   Heil, Sarah H ^c,d   Salisbury, Amy L ^b,e   Stine, Susan M ^f   Martin, Peter R ^g   Jones, Hendrée E ^h  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF VERMONT   (United States)

^e Wayne State University ^*  (United States)

^f WAYNE STATE UNIVERSITY   (United States)

^g VANDERBILT UNIVERSITY   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Buprenorphine; Methadone; Neonatal abstinence; Pregnancy

Indexed keywords

BUPRENORPHINE; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; BIRTH WEIGHT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; LENGTH OF STAY; MULTICENTER STUDY; NEWBORN; OPIATE ADDICTION; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL EXPOSURE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SMOKING; STATISTICAL MODEL; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; BIRTH WEIGHT; BUPRENORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT, NEWBORN; LENGTH OF STAY; LINEAR MODELS; METHADONE; MORPHINE; NEONATAL ABSTINENCE SYNDROME; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; SMOKING; YOUNG ADULT;

EID: 84868132752     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2012.04038.x     Document Type: Article

References (34)

1. National Institutes of Health Consensus Development Panel. Effective medical treatment of opiate addiction. JAMA 1998; 280: 1936-1943.
2. Fajemirokun-Odudeyi O., Sinha C., Tutty S., Pairaudeau P., Armstrong D., Phillips T. etal. Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol Reprod Biol 2006; 126: 170-175.
3. Kaltenbach K., Berghella V., Finnegan L. Opioid dependence during pregnancy: effects and management. Obstet Gynecol Clin North Am 1998; 25: 139-151.
4. Jarvis M. A., Schnoll S. H. Methadone treatment during pregnancy. J Psychoact Drugs 1994; 26: 155-161.
5. Finnegan L. P., Kaltenbach K. Neonatal abstinence syndrome. In: Hoekelman R. A., Friedman S. B., Nelson N. M., Seidel H. M., editors. Primary Pediatric Care, 2nd edn. St Louis, MO: Mosby Year Book; 1992, p. 1367-1378.
6. Berghella V., Lim P. J., Hill M. K., Cherpes J., Chennat J., Kaltenbach K. Maternal methadone dose and neonatal withdrawal. Am J Obstet Gynecol 2003; 189: 312-317.
7. Lainwala S., Brown E. R., Weinschenk N. P., Blackwell M. T., Hagadorn J. I. A retrospective study of length of hospital stay in infants treated for neonatal abstinence syndrome with methadone versus oral morphine preparations. Adv Neonatal Care 2005; 5: 265-272.
8. Cleary B. J., Donnelly J., Strawbridge J., Gallagher P. J., Fahey T., Clarke M. etal. Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. Addiction 2010; 105: 2071-2084. doi:10.1111/j.1360-0443.2010.03120.x.
9. Dryden C., Young D., Hepburn M., Mactier H. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. Br J Obstet Gynaecol 2009; 6: 665-671.
10. Dashe J. S., Sheffield J. S., Olscher D. A., Todd S. J., Jackson G. L., Wendel G. D. Jr. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol 2002; 100: 1244-1249.
11. McCarthy J. J., Leamon M. H., Parr M. S., Anania B. High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. Am J Obstet Gynecol 2005; 193: 606-610.
12. Seligman N. S., Salva N., Hayes E. J., Dysart K. C., Pequignot E. C., Baxter J. K. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol 2008; 199: 396.e1-3967.
13. Kuschel C. A., Austerberry L., Cornwell M., Couch R., Rowley R. S. Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome? Arch Dis Child Fetal Neonatal Ed 2004; 89: F390-393.
14. Choo R. E., Huestis M. A., Schroeder J. R., Shin A. S., Jones H. E. Neonatal abstinence syndrome in methadone-exposed infants is altered by the level of prenatal tobacco exposure. Drug Alcohol Depend 2004; 75: 253-260.
15. Velez M. L., Jansson L. M., Schroeder J., Williams E. Prenatal methadone exposure and neonatal neurobehavioral functioning. Pediatr Res 2009; 66: 704-709.
16. Brown H. L., Britton K. A., Mahaffey D., Brizendine E., Hiett A. K., Turnquest M. A. Methadone maintenance in pregnancy: a reappraisal. Am J Obstet Gynecol 1998; 179: 459-463.
17. Bakstad B., Sarfi M., Welle-Strand G., Ravndal E. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. Eur Addict Res 2009; 15: 128-134.
18. Winklbaur B., Baewert A., Jagsch R., Rohrmeister K., Metz V., Aeschbach Jachmann C. etal. Association between prenatal tobacco exposure and outcome of neonates born to opioid-maintained mothers. Implications for treatment. Eur Addict Res 2009; 15: 150-156.
19. Wouldes T. A., Woodward L. J. Maternal methadone dose during pregnancy and infant clinical outcome. Neurotoxicol Teratol 2010; 32: 406-413.
20. Jansson L. M., DiPietro J. A., Elko A., Velez M. Infant autonomic functioning and neonatal abstinence syndrome. Drug Alcohol Depend 2010; 109: 198-204.
21. Coghlan D., Milner M., Clarke T. A., Lambert I., McDermott C., McNally M. etal. Neonatal abstinence syndrome. Ir Med J 1999; 92: 232-236.
22. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication no. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.
23. Johnson R. E., Jones H. E., Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2002; 70: S87-101.
24. Lejeune C., Simmat-Durand L., Aubisson S. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high dose buprenorphine substitution. Drug Alcohol Depend 2006; 82: 250-257.
25. Jones H. E., Kaltenbach K., Heil S., Stine S., Coyle M., Arria A. etal. Neonatal abstinence syndrome following methadone or buprenorphine exposure. N Engl J Med 2010; 363: 2320-2331.
26. Jones H. E., Fischer G., Heil S. H., Kaltenbach K., Martin P. R., Coyle M. G. et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER)-approach, issues and lessons learned. Addiction 2012; 107 (Suppl. 1): 28-35.
27. Dysart K., Hsieh H. C., Kaltenbach K., Greenspan J. S. Sequela of preterm versus term infants born to mothers on a methadone maintenance program: differential course of neonatal abstinence syndrome. J Perinat Med 2007; 35: 344-346.
28. Lui A. J. W., Sithamparanathan S., Jones M. P., Cook C. M., Manan R. Growth restriction in pregnancies of opioid-dependent mothers. Arch Dis Child Fetal Neonatal Ed 2010; 95: F258-262.
29. Lewis R. M., Greenwood S. L., Cleal J. K., Crozier S. R., Verrall L., Inskip H. M. etal. Maternal muscle mass may influence system A activity in human placenta. Placenta 2010; 31: 418-422.
30. Domenici C., Cuttano A., Nardini V., Varese L., Ghirri P., Boldrini A. Drug addiction during pregnancy: correlations between the placental health and the newborn's outcome-elaboration of a predictive score. Gynecol Endocrinol 2009; 25: 786-792.
31. McCarthy J. J., Leamon M. H., Stenson G., Biles L. A. Outcomes of neonates conceived on methadone maintenance therapy. J Subst Abuse Treat 2008; 35: 202-206.
32. Almario C. V., Seligman N. S., Dysart K. C., Berghella V., Baxter J. K. Risk factors for pre-term birth among opiate-addicted gravid women in a methadone treatment program. Am J Obstet Gynecol 2009; 201: 326e.1-3266.
33. Jansson L. M., Dipietro J. A., Elko A., Velez M. Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates. J Matern Fetal Neonatal Med 2007; 20: 677-685.
34. Moses-Kolko E. L., Bogen D., Perel J., Bregar A., Uhl K., Levin B. etal. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors. JAMA 2005; 293: 2372-2383.